Therapies for<unk><unk>  cell lung cancer<unk> <unk>  include cytotoxic combination chemotherapy (first line), combination chemotherapy with bevacizumab or cetuximab, EGFR tyrosine kinase inhibitors, EML4-ALK inhibitors in patients with EML-ALK translocations, and immune checkpoint inhibition with nivolumab for selected patients with squamous or<unk> -squamous metastatic. Maintenance therapy following first-line chemotherapy, include endobronchial laser therapy or brachytherapy (for obstructing lesions) and external-beam radiation therapy (primarily for palliation of local symptomatic tumor growth). Local therapies (ambulatory catheter drainage, pleurodesis or mediastinal window) plus therapy for systemic metastasis is the preferred combination for patients with<unk> <unk>  M1a<unk><unk>  cell lung cancer.  Patients with solitary site metastasis<unk> <unk>  M1b) should be treated according to the site of metastasis.
Non small cell lung cancer medical therapy stage IV
Non small cell lung cancer medical therapy stage III
Non small cell lung cancer medical therapy stage II
Non small cell lung cancer medical therapy metastatic cancer
Large cell carcinoma of the lung medical therapy
Small cell carcinoma of the lung medical therapy
Squamous cell carcinoma of the lung medical therapy
Non small cell lung cancer future or investigational therapies